Tissue Repair Ltd (AU:TRP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tissue Repair Ltd, listed on the ASX, reported a surge in TR Pro+® sales by 27% over the previous quarter, marking strong market acceptance with over 240 clinics placing orders. The company is advancing its TR987® treatment for chronic wounds, with significant progress in clinical trial preparations and the production of the Glucoprime® API. The company’s cash position remains robust at $15.9 million as of September 2024, despite net cash outflows driven by ongoing development and commercialization efforts.
For further insights into AU:TRP stock, check out TipRanks’ Stock Analysis page.